Dr. Richard Maziarz
Dr. Richard Maziarz is the medical director of the adult blood and marrow stem cell transplant and cellular therapy program at the OHSU Knight Cancer Institute. Dr. Maziarz received his Medical Doctorate at Harvard University and completed his immunology fellowship at Dana-Farber Cancer Institute.
Dr. Maziarz specializes in bone marrow transplantation and blood cancers. He is highly interested in determining how the immune system fights cancer along with how it responds to bone marrow transplant. Other areas of interest include leukemia, lymphoma, myeloma, GVHD, and CAR-T therapy.
At last count, Dr. Maziarz has published 263 papers, as well as thirty-eight book chapters and reviews.
Dr. Mazen Noureddin
Dr. Mazen Noureddin is a hepatologist at Cedars Sinai in Los Angeles. He completed his residency at the University of Southern California and completed a hepatology fellowship at the NIH and gastroenterology fellowship at University of California San Diego.
Dr. Noureddin has led efforts in several breakthrough clinical trials targeting new therapies in patients with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), including those with advanced fibrosis and cirrhosis. He also focuses on the underlying mechanisms of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), liver transplant, liver cancer, new imaging modalities, and exploring new treatments.
His work has been featured in Gastroenterology, Hepatology, and The American Journal of Gastroenterology, among many others.
Dr. Norman Gaylis
Dr. Norman Gaylis is recognized as one of the country’s leaders in the field of arthritis and rheumatic diseases. He is board-certified in Internal Medicine and Rheumatology and has been a practicing Rheumatologist in the greater Miami area for more than 35 years. Dr. Gaylis completed his training as a rheumatologist at the University of Miami, where he served on the clinical faculty for many years.
Dr. Gaylis is the owner and chief operating officer of AARDS Research, Inc., a clinical research organization specializing in clinical research trials for autoimmune diseases and the Medical Director of Infusion and Immunotherapy Center of South Florida (IIC.) He has been a Principal Investigator in over 200 clinical trials for new pharmaceutical products for the treatment of Rheumatoid Arthritis, Osteoarthritis, Osteoporosis, Systemic Lupus, Lupus Nephritis, Gout, and Sjogren’s syndrome.
Dr. Gaylis has presented numerous scientific papers and has conducted medical meetings around the United States and internationally. He is the author of multiple peer-reviewed articles, focused in particular on the subjects of rheumatoid arthritis, magnetic resonance imaging in rheumatology, and other rheumatic disorders. He is the past medical director for the Rheumatology division at Cardinal Health, a speaker and consultant for numerous pharmaceutical companies and the recipient of many awards and honors, as well as an active member of the American College of Rheumatology and the Rheumatology Research Foundation.
Dr. Gero Hütter
Gero Hütter is a German hematologist who developed and performed the first allogeneic transplantation with natural CCR5 depleted stem cells in a leukemia patient with HIV-infection in 2004, during his residency in hematology, oncology and transfusion medicine at Charité Hospital in Berlin, Germany. Since then, the patient who is now known as “the Berlin patient,” has not resumed antiretroviral therapy, nor has he had a relapse of HIV disease.
In 2009, Dr Hütter became the head of the stem cell unit of the Institute of Transfusion Medicine and Immunology Mannheim of the Heidelberg University. There, he directs the research group of personalized stem therapy, which is supported by a grant from the Bill & Melinda Gates foundation.
Dr. Hope Rugo
Dr. Hope Rugo is the Director of the Breast Oncology Clinical Trials Program at UCSF. She is the principal investigator for multiple clinical trials studying novel targeted therapeutics combined with standard treatments to improve clinical results in early and late-stage breast cancer. She is also researching cognitive function in patients receiving chemotherapy for breast cancer as well as ways to reduce toxicity from therapy.
Dr. Rugo has established collaborations with several large academic medical centers to expand the novel therapies that are available to patients. She is an active member of the national cooperative group, CALGB, a founding member of the Breast Cancer Research Consortium, and an investigator in the UCSF Breast SPORE (the Bay Area Specialized Program of Research Excellence in Breast Cancer).
Dr. Rugo teaches medical students and physicians, and regularly lectures locally, nationally, and internationally. At UCSF, Dr. Rugo runs the Breast Forum, an open bimonthly evening educational session for breast cancer patients, families, and friends from throughout the Bay Area. She is widely published and highly regarded in the field of oncology.
Dr. Lishomwa (Lish) Ndhlovu
Dr. Ndhlovu is a Professor of Immunology at Weill Cornell Medicine in the Department of Medicine, Division of Infectious Disease. After completing medical school training, he went on to receive his Ph.D. from Tohoku University in Japan and completed postdoctoral fellowship in HIV immunology at the University of California, San Francisco.
Dr. Ndhlovu’s research focuses on two themes: (1) understanding the early changes to myeloid cells during acute HIV infection that could be important in the development of cognitive impairment and evaluating strategies to prevent, slow or eliminate these brain abnormalities while optimizing the quality of life outcomes and (2) a focus on discoveries in T cell biology leading to new paradigms for eradicating HIV.
Seventy peer-reviewed journals have reported his research results.
Dr. Eric Mininberg
Dr. Eric Mininberg is a board-certified medical oncologist at Piedmont Cancer Institute and a Diplomat of the American Board of Internal Medicine. He graduated from Dartmouth College in 1993 with a degree in government and obtained a medical degree from the University of Virginia School of Medicine. He completed his residency at the University of Virginia Medical Center. He was a Hematology fellow at Baylor University and a Medical Oncology fellow at the University of Texas MD Anderson Cancer Center.
Dr. Mininberg is the recipient of numerous honors and awards. He was inducted in 1989 as a member of Cum Laude Society with St. Albans School in Washington, DC. While at The University of Texas MD Anderson Cancer Center, he was honored with the Elsa U. Pardee Foundation Grant for Community Oncology. As a fellow in 2003 he was awarded the American Society of Clinical Oncology Merit Award. He holds memberships with the Dartmouth and University of Virginia Alumni Associations, as well as the American and Georgia Societies of Clinical Oncology.
He has numerous publications and abstracts in Hematology and Oncology.
Dr. Mininberg will specifically support CytoDyn’s clinical trial enrollment in the southeast region and further exploration of leronlimab PRO 140’s indications in oncology.
Dr. Jonah Sacha
Dr. Sacha graduated cum laude from the University of Missouri-Columbia in 2003 with a B.A. in German and B.S. in Biology. After receiving his Ph.D. in Medical Microbiology & Immunology from the University of Wisconsin-Madison in 2007, he joined the faculty at UW-Madison, where he researched the characteristics of effective retrovirus-specific CD8+ and CD4+ T cells. In 2011, he joined the Oregon Health & Science University and has appointments in both the Vaccine & Gene Therapy Institute and Oregon National Primate Research Center.
Dr. Sacha will lead CytoDyn’s team efforts in HIV PreP and HIV cure.